Table IV.
Clinical, hematological and anthropological features of paraneoplastic arthritides
| Author | CRP | ESR | Mimicker | Age | Arthritis treatment | Response to AT | Tumor medical treatment | Tumor surgical treatment | Response of articular manifestations to tumor treatments |
|---|---|---|---|---|---|---|---|---|---|
| Longley et al. 1986 [26] | n.a. | n.a. | n.a. | 49 (g.u.) | NSAIDs, GCs | Partial | n.a. | n.a. | n.a. |
| Lambert, Nuki 1992 [39] | n.a. | 43 | RA | 63 M | NSAIDs, cyclophosphamide | Partial | CHT (nos) | Penis amputation | n.a. |
| Cohen et al. 1993 [27] | n.a. | 73 | AxSPA | 61 F | Piroxicam, SSZ, prednisone, AZT | n.a. | n.a. | n.a. | n.a. |
| Drenth et al. 1995 [38] | n.a. | 135 | RA | 49 F | Naproxen, indometacin | Poor | Oral cyclophosphamide (100 mg/m2 days 1–14), 5-fluorouracil (600 mg/m2 days 1 and 8), methotrexate (40 mg/m2 days 1 and 8), and prednisone (30 mg/day) | n.p. | Remission after 3 months of CHT |
| Stummvoll et al. 2001 [5] | 4.6 (1), 2.9 (2) | 53 (1), 35 (2) | RA (1) | 60 M | Diclofenac (1), Diclofenac (2) | Poor (1) Partial (2) | Cisplatin and etoposide soldesam, 5HT3 inhibitors (1), 5-fluorouracil and leucovorin (2) | Lobectomy and lymphadenectomy (1), surgery (2) | Response after chemotherapy (1), response after surgery (2) |
| Lima et al. 2002 [31] | n.a. | n.a. | n.a. | 35 F | GCs | Poor | Cyclophosphamide, doxorubicin, vincristine, and prednisone | n.ap. | Improvement |
| Glinkov et al. 2003 [6] | n.a. | n.a. | n.a. | 23 F | GCs, NSAIDs | Poor | n.a. | Resectomy | Full remission |
| Mok, Kwan 2003 [7] | 2.2 | 80 | RA | 69 F | NSAIDs, SSZ, GCs | Poor to NSAIDs, partial to SSZ and GCs | n.p. | n.p. | Partial improement |
| Wiese et al. 2004 [40] | n.a. | 26 | Reactive arthritis | 34 F | NSAIDs | Poor | n.p. | Resectomy | Full remission |
| Ardalan, Shoja 2007 [28] | n.a. | 53 | RA | 47 M | MPPT, PDN | Poor | VAD | n.a. | Full remission |
| Bivalacqua et al. 2007 [21] | n.a. | n.a. | RA | 52 M | n.a. | n.a. | n.a. | Lobectomy + cystectomy | Full remission |
| Cantini et al. 2007 [16] | n.a. | n.a. | n.a. | 57 M | NSAIDs | Poor | n.a. | Resectomy | Full remission |
| Morel et al. 2008 [15] | ↑ | n.a. | RA | 57 (16 M/10 F) | NSAIDs, GCs, csDMARDs | NSAIDS – good (45%) GCs –excellent (91%) csDMARDs (poor) | n.a. | n.a. | n.a. |
| Tedeschi et al. 2017 [29] | 19.1 | 115 | Pseudo gout | 75 M | Naproxen, MPPT colchicine, GCs injections | Partial | Azacitidine | n.a. | Poor |
| Zupancic et al. 2008 [17] | 1.5 | 106 | n.a. | 43 M | Naproxen, prednisone | Poor | Cisplatin + etoposide | n.p. | Good |
| Bahat et al. 2009 [9] | n.a. | n.a. | RA | 72 M (1), 63 F (2) | NSAIDS, PDN, MTX, plaquenil (1) | Good (1), poor (2) | COP (1), 5-FU (2) | n.a. (1), palliative (2) | Partial (1), good (2) |
| Kumar et al. 2009 [8] | 19.1 | 115 | RA | 58M | Naproxen, MPPT, colchicine, GCs injections | Partial | Azacitidine | n.a. | Poor |
| Larson et al. 2011 [19] | 3.4 | 35 | RA | 45 F | Ibuprofen, GCs | Poor | n.a. | n.a. | n.a. |
| Kobak 2013 [25] | 1.5 | 106 | n.a. | 43 M | Naproxen, prednisone | Poor | Cisplatin + etoposide | n.p. | Good |
| Raja et al. 2010 [37] | n.a. | n.a. | RA | 40 F | NSAIDS, PDN, MTX, plaquenil (1) | Good (1), poor (2) | COP (1), 5-FU (2) | n.a. (1), palliative (2) | Partial (1), good (2) |
| Han et al. 2012 [18] | Normal | 44 | RA | 55 F | n.a. | n.a. | Gefitinib | n.a. | Good |
| Aruch et al. 2013 [32] | n.a. | n.a. | n.a. | 38 M | Dexamethasone | Poor | ABVD | n.a. | Full remission |
| Ochi et al. 2012 [10] | 15.6 | 104 | RA | 71 M | n.a. | n.a. | n.a. | Total gastrectomy | Full remission after surgery |
| Prashanth et al. 2013 [33] | Normal | Normal | n.c. | 10 M | Aspirin, naproxen, MPPT | Poor | n.a. | n.a. | Full remission with therapy |
| Handy et al. 2015 [34] | 7.1 | 122 | RA | 61 F | NSAIDs, GCs | Poor | CYC, vincristine, doxorubicin, and dexamethasone | n.ap. | Poor |
| Kisacik et al. 2014 [22] | 65.1 ±85.5 | 58.5 ±31.9 | RA | 58.02 ±15.3 | n.a. | n.a. | n.a. | n.a. | n.a. |
| Watson et al. 2015 [20] | 11.8 (1), 1.2 (2) | 21 (1), n.a. (2) | RA (1 + 2) | 80 F (1), 71 F (2) | NSAIDs, GCs | Poor to NSAIDs, good to MPPT (1), poor to NSAIDs and GCs (2) | RT and CHT nos (1) | n.a. (1), lobectomy (2) | Remission (1), Remission after surgery (2) |
| Erlij et al. 2016 [35] | 110 | RA | 46 M | MPPT, prendisolone | Partial | Doxorubicin, bleomycin, vinblastine and dacarbazine | n.ap. | Full remission | |
| Levi Sandri et al. 2016 [13] | n.a. | n.a. | RA | 19 M | n.a. | n.a. | n.a. | n.a. | n.a. |
| Gamage et al. 2018 [36] | ↑ (n.r.) | ↑ (n.r.) | RA | 45 M | NSAIDs, colchicine | Poor | RCHOP | n.i. | Full remission |
| Iqbal et al. 2018 [30] | ↑ (n.r.) | ↑ (n.r.) | Pseudo-gout | 83 M | GCs | Good | Azacitidine | n.ap. | Full remission |
| Eidenschink et al. 2019 [24] | 15.6 | 69 | n.a. | 73 M | Naproxen | Partial | n.a. | n.a. | Improvement |
| Briones-Figueroa et al. 2019 [14] | 9.5 | 51 | n.a. | 69 M | GCs (prednisone) | Poor | RT and CHT | n.p. | Improvement |
| Rabah et al. 2020 [11] | 10.43 | 120 | RA | 83 M | NSAIDs, PDN | Poor | n.a. | n.a. | n.a. |
| Sachdev Manjit Singh et al. 2021[23] | n.a. (1) | 61 (1), raised (2) | SPA (1), RA (2) | 65 F (1), 64 M (2) | PDN, SSZ (1 + 2) | Poor (1) | Gefitinib (1), carboplatin + paclitaxel + gemcitabine (2) | n.p. | Improvement (1), n.a. (2) |
| Silvèrio-Antònio et al. 2021 [12] | 17.3 | 94 | RA | 64 M | Dexamethasone, HCQ, PDN | Good | Cisplatin, 5-FU, trastuzumab | n.p. | Poor |
ABVD – doxorubicin, bleomycin, vinblastine, and dacarbazine, CHT – choline transporter, CYC – cyclophosphamide, GCs – glucocorticosteroids, F – female, HCQ – hydroxychloroquine, M – male, MPPT – methylprednisolone, MTX – methotrexate, n.a. – not assessed, n.p. – not performed, NSAIDs – non-steroidal anti-inflammatory drugs, PDN – prednisone, RA – rheumatoid arthritis, RCHOP – rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisolone, SPA – spondyloarthropathy, SSZ – salazopyrin, 5-FU – fluoropyrimidine 5-fluorouracil.